AR115766A1 - Derivados de tirosinamida como inhibidores de la quinasa rho - Google Patents
Derivados de tirosinamida como inhibidores de la quinasa rhoInfo
- Publication number
- AR115766A1 AR115766A1 ARP190101969A ARP190101969A AR115766A1 AR 115766 A1 AR115766 A1 AR 115766A1 AR P190101969 A ARP190101969 A AR P190101969A AR P190101969 A ARP190101969 A AR P190101969A AR 115766 A1 AR115766 A1 AR 115766A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- aryl
- heteroaryl
- group
- 6haloalkyl
- Prior art date
Links
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical class NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 title 1
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000007247 enzymatic mechanism Effects 0.000 abstract 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000000568 rho-Associated Kinases Human genes 0.000 abstract 1
- 108010041788 rho-Associated Kinases Proteins 0.000 abstract 1
- 239000011435 rock Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de fórmula (1) que inhiben la quinasa Rho, que son derivados de dihidropirimidin-carboxamida bicíclicos, métodos para prepararlos, composiciones farmacéuticas que los contienen y su uso terapéutico. En particular, los compuestos de la presente pueden ser útiles en el tratamiento de diversos trastornos asociados a los mecanismos de las enzimas ROCK, por ejemplo, enfermedades pulmonares, incluyendo asma, enfermedad pulmonar obstructiva crónica (EPOC), fibrosis pulmonar idiopática (FPI) e hipertensión pulmonar arterial (HPA). Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), donde X¹ y X² son independientemente un grupo CH o un átomo de nitrógeno; p es cero o un número entero entre 1 y 3; de estar presente, cada R es un halógeno; R⁰ y R¹ se seleccionan independientemente del grupo que consiste en -H, C₁₋₆alquilo, C₃₋₁₀cicloalquilo, arilo, heteroarilo y C₃₋₆heterocicloalquilo, donde cada arilo, heteroarilo o C₃₋₆heterocicloalquilo también puede estar sustituido independientemente con uno o más grupos seleccionados entre halógeno u -OH; R² y R³, que son idénticos o diferentes, se seleccionan del grupo que consiste en -H, C₁₋₆alquilo, C₁₋₆haloalquilo, C₁₋₆hidroxialquilo, C₁₋₆aminoalquilo, C₁₋₆alcoxiC₁₋₆alquilo, C₃₋₁₀cicloalquilo, C₃₋₈heterocicloalquilo, arilo, heteroarilo, arilC₁₋₆alquilo, heteroarilC₁₋₆alquilo, C₃₋₈cicloalquilC₁₋₆alquilo y C₃₋₈heterocicloalquilC₁₋₆alquilo, donde cada arilo, heteroarilo, cicloalquilo, heterocicloalquilo también puede estar sustituido independientemente con uno o más grupos seleccionados entre halógeno, -CN, -OH, C₁₋₈alquilo, C₃₋₆cicloalquilo, C₁₋₆haloalquilo, C₁₋₁₀alcoxilo, heterocicloalquilo, arilo, arilC₁₋₆alquilo, -C(O)NR⁷R⁸, C₁₋₆aminoalquilo, C₁₋₆hidroxialquilo, C₁₋₆alcoxiC₁₋₆alquilo o C₃₋₈cicloalquilC₁₋₆alquilo; o como alternativa, R² y R³, junto con el átomo de nitrógeno al que están unidos, forman un radical heterocíclico mono o bicíclico, saturado o parcialmente saturado, preferiblemente un radical monocíclico de entre 4 y 6 miembros, donde al menos un átomo de carbono en un anillo del radical heterocíclico puede ser reemplazado por al menos un heteroátomo seleccionado independientemente entre N, NH, S u O y/o puede comprender un grupo sustituyente oxo (=O), donde el radical heterocíclico también puede comprender una disustitución espiro o una sustitución en dos anillos adyacentes o vecinales para formar un anillo adicional de 5 ó 6 miembros cíclico o heterocíclico, saturado, parcialmente saturado o aromático, donde el radical heterocíclico también puede estar sustituido con uno o más grupos seleccionados del grupo que consiste en halógeno, -OH, -NR⁷R⁸, CH₂NR⁷R⁸, C₁₋₆alquilo, C₁₋₆alquilsulfonilo, C₁₋₆haloalquilo, C₁₋₆hidroxialquilo, C₂₋₆alquenilo, C₂₋₆alquinilo, C₂₋₆hidroxialquinilo, C₁₋₆alcoxiC₁₋₆alquilo, C₁₋₆alcanilo, -C(O)NR⁷R⁸, C₃₋₆cicloalquilcarbonilo, C₃₋₆heterocicloalquilcarbonilo, arilC₁₋₆alquilo, arilalcanilo, arilsulfonilo, arilC₁₋₆alquilsulfonilo, heteroarilC₁₋₆alquilo, heteroarilcarbonilo, heteroarilsulfonilo, heteroariloxilo, C₃₋₆cicloalquilo, incluyendo cicloalquil-ilo, C₃₋₈cicloalquilC₁₋₆alquilo, C₃₋₆heterocicloalquilC₁₋₆alquilo, arilo y heteroarilo, donde cada cicloalquilo, arilo o heteroarilo también puede estar sustituido con halógeno, -OH, C₁₋₈alquilo, C₁₋₆haloalquilo, C₁₋₁₀alcoxilo, C₁₋₆alquiltiol, C₁₋₆aminoalquilo, C₁₋₆aminoalcoxilo, -C(O)NR⁷R⁸ o C₁₋₆alquilsulfonilo; R⁴ y R⁵ se seleccionan independientemente del grupo que consiste en H y C₁₋₆alquilo; R⁶ se selecciona del grupo que consiste en H, C₁₋₆alquilo y C₁₋₆haloalquilo; R⁷ y R⁸ se seleccionan independientemente del grupo que consiste en -H, C₁₋₆alquilo, C₁₋₆haloalquilo, C₁₋₆hidroxialquilo, C₁₋₆aminoalquilo, C₁₋₆alcoxilo, C₁₋₆alcoxiC₁₋₆alquilo, C₃₋₆heterocicloalquilC₁₋₆alquilo, C₃₋₆cicloalquilo, arilo, heteroarilo y C₃₋₆heterocicloalquilo, donde cada arilo, heteroarilo o C₃₋₆heterocicloalquilo puede estar sustituido independientemente con uno o más grupos seleccionados entre halógeno, -OH o C₁₋₆alquilo; o sales o solvatos farmacéuticamente aceptables de éste.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18183733 | 2018-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115766A1 true AR115766A1 (es) | 2021-02-24 |
Family
ID=62975943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101969A AR115766A1 (es) | 2018-07-16 | 2019-07-11 | Derivados de tirosinamida como inhibidores de la quinasa rho |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210284639A1 (es) |
| EP (1) | EP3823969A1 (es) |
| JP (1) | JP2021529819A (es) |
| KR (1) | KR20210032977A (es) |
| CN (1) | CN112752757B (es) |
| AR (1) | AR115766A1 (es) |
| AU (1) | AU2019304472A1 (es) |
| BR (1) | BR112021000101A2 (es) |
| CA (1) | CA3104955A1 (es) |
| MA (1) | MA53164A (es) |
| MX (1) | MX2021000270A (es) |
| TW (1) | TW202019923A (es) |
| WO (1) | WO2020016129A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023552899A (ja) | 2020-12-15 | 2023-12-19 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｒｈｏ－キナーゼ阻害剤としてのジヒドロフロピリジン誘導体 |
| MX2023005865A (es) | 2020-12-15 | 2023-06-05 | Chiesi Farm Spa | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. |
| MX2023005866A (es) | 2020-12-15 | 2023-06-05 | Chiesi Farm Spa | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. |
| WO2023110700A1 (en) | 2021-12-13 | 2023-06-22 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2503646C (en) | 2002-10-28 | 2011-09-27 | Bayer Healthcare Ag | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| JP2008503492A (ja) | 2004-06-17 | 2008-02-07 | スミスクライン・ビーチャム・コーポレイション | Ｒｈｏ−キナーゼの新規阻害剤 |
| JP5212101B2 (ja) * | 2005-09-02 | 2013-06-19 | アステラス製薬株式会社 | 新規化合物 |
| WO2009079008A1 (en) | 2007-12-19 | 2009-06-25 | Yangbo Feng | Benzopyrans and analogs as rho kinase inhibitors |
| EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2331507A2 (en) | 2008-09-18 | 2011-06-15 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
| WO2012007539A1 (en) | 2010-07-14 | 2012-01-19 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
| CN103547575B (zh) * | 2011-06-10 | 2016-08-17 | 奇斯药制品公司 | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
| HUE033962T2 (en) | 2013-01-29 | 2018-01-29 | Redx Pharma Plc | Pyridine derivatives as soft rock (RHO kinase) inhibitors |
| TWI800498B (zh) | 2016-12-21 | 2023-05-01 | 義大利商吉斯藥品公司 | 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物 |
| EP3573987B1 (en) * | 2017-01-30 | 2021-03-10 | Chiesi Farmaceutici S.p.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
-
2019
- 2019-06-24 TW TW108121992A patent/TW202019923A/zh unknown
- 2019-07-11 AR ARP190101969A patent/AR115766A1/es not_active Application Discontinuation
- 2019-07-12 US US17/260,631 patent/US20210284639A1/en not_active Abandoned
- 2019-07-12 CN CN201980047406.6A patent/CN112752757B/zh active Active
- 2019-07-12 KR KR1020217003030A patent/KR20210032977A/ko not_active Withdrawn
- 2019-07-12 MA MA053164A patent/MA53164A/fr unknown
- 2019-07-12 WO PCT/EP2019/068832 patent/WO2020016129A1/en unknown
- 2019-07-12 AU AU2019304472A patent/AU2019304472A1/en not_active Abandoned
- 2019-07-12 JP JP2021501323A patent/JP2021529819A/ja not_active Ceased
- 2019-07-12 CA CA3104955A patent/CA3104955A1/en active Pending
- 2019-07-12 MX MX2021000270A patent/MX2021000270A/es unknown
- 2019-07-12 BR BR112021000101-8A patent/BR112021000101A2/pt unknown
- 2019-07-12 EP EP19744641.2A patent/EP3823969A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000270A (es) | 2021-03-26 |
| CN112752757B (zh) | 2024-01-12 |
| KR20210032977A (ko) | 2021-03-25 |
| CA3104955A1 (en) | 2020-01-23 |
| EP3823969A1 (en) | 2021-05-26 |
| JP2021529819A (ja) | 2021-11-04 |
| BR112021000101A2 (pt) | 2021-03-30 |
| US20210284639A1 (en) | 2021-09-16 |
| TW202019923A (zh) | 2020-06-01 |
| CN112752757A (zh) | 2021-05-04 |
| WO2020016129A1 (en) | 2020-01-23 |
| MA53164A (fr) | 2021-05-26 |
| AU2019304472A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
| AR115766A1 (es) | Derivados de tirosinamida como inhibidores de la quinasa rho | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR115092A1 (es) | Inhibidores de magl | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR095279A1 (es) | N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100997A1 (es) | Derivados de piridina como inhibidores de histona demetilasa | |
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR108185A1 (es) | Amidas terciarias y método para su uso | |
| AR122096A2 (es) | Compuestos profármacos de creatina y composiciones que los comprenden | |
| AR113947A1 (es) | Derivados de azaindol como inhibidores de rho-quinasa | |
| AR126914A1 (es) | Inhibidores de ras novedosos | |
| AR123977A1 (es) | 1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfr | |
| AR123185A1 (es) | Compuestos y composiciones para inhibir ezh2 | |
| AR109651A1 (es) | Compuestos de piridina y pirazina como inhibidores de ripk2 | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |